Management of women treated with buprenorphine during pregnancy

American Journal of Obstetrics and Gynecology

Volumn 205, Issue 4, 2011, Pages 302-308

  Alto, William A ^a   O'Connor, Alane B ^a  

^a Maine Dartmouth Family Medicine Residency   (United States)

Author keywords

Buprenorphine; Opiate substitution; Pregnancy

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NALOXONE; PROBUPHINE; UNCLASSIFIED DRUG; NARCOTIC AGENT;

ANALGESIA; BREAST FEEDING; DELIVERY; DRUG ABUSE; DRUG ACTIVITY; HOSPITAL DISCHARGE; HUMAN; LABOR; OBSTETRIC PROCEDURE; OPIATE ADDICTION; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK FACTOR; SCREENING TEST; TREATMENT PLANNING; WITHDRAWAL SYNDROME; FEMALE; OPIATE SUBSTITUTION TREATMENT;

BUPRENORPHINE; FEMALE; HUMANS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY;

EID: 84855163810     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.04.001     Document Type: Review

References (74)

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: volume I. Summary of National Findings (Office of Applied Studies, NSDUH series H-38A, HHS publication no. SMA 10-4856 findings). 2010. Rockville, MD: Department of Health and Human Services.
2. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981-5.
3. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) series 40. Department of Health and Human Services publication no. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. Available at: http://www.ncbi.nlm.gov/books/NBK14901/. Accessed Jan. 24, 2011.
4. Kakko J, Svanborg KD, Kreek MJ, Heilig M. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 2003;361:662-8. (Pubitemid 36246548)
5. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92:854-8. (Pubitemid 28487688)
6. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005:CD004330.
7. Minozzi S, Amato L, Davoli M. Maintenance treatments for opiate dependent adolescent. Cochrane Database Syst Rev 2009: CD007210.
8. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2008:CD004147.
9. Drug Information Online. Pharmaceutical sales 2009. Available at http://www.drugs. com/top200.html. Accessed Dec. 7, 2010.
10. Greene P. Outpatient drug utilization trends for buprenorphine years 2002-2009. Available at: http://buprenorphine.samhsa.gov/meetings.html. Accessed Dec. 22, 2010.
11. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-31.
12. Nocon JJ. Buprenorphine in pregnancy: the advantages (letter to the editor). Addiction 2006;101:608-9.
13. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96:69-78.
14. Binder T, Vavrinková B. Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birth weight of newborns, early postpartum adaption and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008;29:80-6.
15. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79:1-10. (Pubitemid 41557119)
16. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend 2006;82:250-7.
17. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101:275-81. (Pubitemid 43351601)
18. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009;104:73-7.
19. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010;5:159-64.
20. Unger A, Jung E, Winklbaur B, Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis 2010; 29:217-30.
21. Finnegan LP, Kondall SR. Perinatal substance abuse: drug dependence, motherhood, and the newborn. In: Galanter M, Kleber HD, eds. The American psychiatric publishing text-book of substance abuse treatment. Arlington, VA: APP; 2008:565-75.
22. Kahilia H, Saisto, T, Kivitie-Kallio S, Haukkamaa M, Halmesmäki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007;86:185-90.
23. Goler, N, Armstrong, M, Taillac C, Osejo, V. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol 2008;28:597-603.
24. Winklbaur B, Baewert A, Jagsch R, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioidmaintained mothers. Implications for Treatment. Eur Addict Res 2009;15:150-6.
25. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004;99:209-14. (Pubitemid 38250755)
26. Simmat-Durand L, Lejeune C, Laureat G. Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 2009;142:119-23.
27. Mawhinney S, Ashe RG, Lowry J. Substance abuse in pregnancy: opioid substitution in a Northern Ireland maternity unit. Ulster Med J 2006;75:187-91. (Pubitemid 44308989)
28. Prochaska JO, Di Clemente CC. Stages and process of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983;51:390-5.
29. Center for Substance Abuse Treatment. Brief interventions and brief therapies for substance abuse treatment improvement. Protocol (TIP) series 34. Department of Health and Human Services publication no. (SMA) 04-3952. Rockville, MD: Substance Abuse and Mental Health Administration; 1999:15. Available at http://www.ncbi.nlm.nih.gov/books/NBK14512/. Accessed March 17, 2011.
30. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008;103:1429-40.
31. Kandall SR. Improving treatment for drugexposed infants. Rockville, MD: US Department of Health and Human Services, Center for Substance Abuse Treatment; 1993.
32. Newman RG. Response to "Transferring methadone-stabilized pregnant patients to buprenorphine." Am J Addict 2006;15:400. (Pubitemid 44373588)
33. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35:245-59.
34. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008: CD002207.
35. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96:683-90. (Pubitemid 32458706)
36. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44:661-80. (Pubitemid 40994078)
37. Dunlop AJ, Panjari M, O'Sullivan H, et al. Clinical guidelines for the use of buprenorphine in pregnancy. Fitzroy (Victoria, Australia): Turning Point Alcohol and Drug Centre; 2003.
38. Greenwald MK, Johanson C-E, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacol 2003;28:2000-9. (Pubitemid 37412109)
39. O'Connor A, Alto W, Musgrave K, et al. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med 2011;24:194-201.
40. Bakaysa S, Heil S, Meyer M. Buprenorphine dose changes during gestation. Amer J Obstet Gynecol 2009;201:S297-8.
41. Wesson DR, Smith DE. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs 2010;42:161-75.
42. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized control trial. JAMA 2010;304:1576-83.
43. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine-and norbuprenorphine-induced analgesic efforts based on pharmacokinetic-pharmacodynamic aspects. J Pharmacol Exp Ther 1995;272:505-10.
44. Kaltenbach K, Berghella V, Finnegan L. Opiate dependence during pregnancy. Effects and management: Obstet Gynecol Clin North Am 1998;25:139-51.
45. Chang G, Carroll KM, Behr HM, Kosten TR. Improving treatment outcome in pregnant opiate-dependent women. J Subst Abuse Treat 1992;9:327-30. (Pubitemid 23052629)
46. Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol 2009;201:326.e1-6.
47. Vermont guidelines for medication assisted treatment (MAT) for pregnant women. Vermont buprenorphine practice guidelines. Vermont Department of Health, Division Alcohol and Drug Abuse Programs. Available at: www.med.uvm.edu/VCHIP/ downloads/VCHIP. Accessed Jan. 30, 2011.
48. Jansson LM, Dipietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011;33:240-3.
49. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006;144:127-34. (Pubitemid 46768231)
50. Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006;82:218-23.
51. Rajani AK, Chitkara R, Halamek LP. Delivery room management of the neonate. Pediatr Clin North Am 2009;56:515-35.
52. Jones HE, O'Grady K, Dahne J, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009;35:151-6.
53. Bryson EO, Lipson S, Gevirtz C. Anesthesia for patients on buprenorphine. Anesthesiol Clin 2010;28:611-7.
54. Jones HE, Johnson RE, Milio L. Post-Cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006;15:258-9.
55. Meyer M, Paranya G, Norris AK, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain 2010;14:939-43.
56. Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007;110: 261-6. (Pubitemid 47356649)
57. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-101. (Pubitemid 36556063)
58. Fischer, G, Johnson RE, Eder H, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95:239-44. (Pubitemid 30111244)
59. Thajam D, Atkinson DE, Sibley CP, Lavender T. Is neonatal abstinence syndrome related to the amount of opiate used? J Obstet Gynecol Neonatal Nurs 2010;39:503-9.
60. Bakstad B, Sarfi M, Welle-Strand GK, Ravndel E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. Eur Addict Res 2009;15:128-34.
61. Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008;84:604-12.
62. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Freidman SB, Nelson NM, et al, eds. Primary pediatric care, 2nd ed. St Louis, MO: Mosby; 1992:1367-78.
63. Jansson LM, Velez M, Harrow C. The opioid exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5:47-55.
64. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007;87:131-8. (Pubitemid 46215932)
65. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010: CD002059.
66. Sarfi M, Martinsen H, Bakstad B, Røislien J, Waal H. Patterns in sleep-wakefulness in threemonth old infants exposed to methadone or buprenorphine. Early Hum Dev 2009;85:773-8.
67. Whitham JN, Spurrier NJ, Sawyer MG, et al. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010:32:280-8.
68. Kahila H, Kivitie-Kallio S, Halmesmäki E, Valanne L, Autti L. Brian magnetic resonance imaging of infants exposed prenatally to buprenorphine. Acta Radiol 2007;48:228-31. (Pubitemid 46396997)
69. Kahila H, Stefanovic V, Loukovaara M, Alfthan H, Hämälä inen E, Halmesmäki E. Prenatal buprenorphine exposure: effects on biochemical markers of hypoxia and early neonatal outcome. Acta Obstet Gynecol Scand 2008;87: 1213-9.
70. Farid WO, Dunlop SA, Tait RJ, Hulse, GK. The effects of maternal administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008;6:125-50. (Pubitemid 352024797)
71. Hale T. Medications and mother's milk, 13th ed. Amarillo, TX: Hale Publishing; 2008.
72. Grimm D, Pauly E, Pöschl J, Linderkamp O, Skopp G. Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005; 27:526-30. (Pubitemid 41098830)
73. Lindemalm S, Nydert P, Svensson J-O, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009;25:199-205.
74. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997;62:569-71. (Pubitemid 28214935)